These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 9813026)
1. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes. Myles T; Church FC; Whinna HC; Monard D; Stone SR J Biol Chem; 1998 Nov; 273(47):31203-8. PubMed ID: 9813026 [TBL] [Abstract][Full Text] [Related]
2. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans. Sheehan JP; Tollefsen DM; Sadler JE J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495 [TBL] [Abstract][Full Text] [Related]
3. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity. Sheehan JP; Wu Q; Tollefsen DM; Sadler JE J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II. Cooper ST; Rezaie AR; Esmon CT; Church FC Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592 [TBL] [Abstract][Full Text] [Related]
5. The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand. Boyle AJ; Roddick LA; Bhakta V; Lambourne MD; Junop MS; Liaw PC; Weitz JI; Sheffield WP BMC Biochem; 2013 Mar; 14():6. PubMed ID: 23496873 [TBL] [Abstract][Full Text] [Related]
6. Molecular mapping of the thrombin-heparin cofactor II complex. Fortenberry YM; Whinna HC; Gentry HR; Myles T; Leung LL; Church FC J Biol Chem; 2004 Oct; 279(41):43237-44. PubMed ID: 15292227 [TBL] [Abstract][Full Text] [Related]
7. Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition. Mitchell JW; Church FC J Biol Chem; 2002 May; 277(22):19823-30. PubMed ID: 11856753 [TBL] [Abstract][Full Text] [Related]
8. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. Van Deerlin VM; Tollefsen DM J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083 [TBL] [Abstract][Full Text] [Related]
9. RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. Jeter ML; Ly LV; Fortenberry YM; Whinna HC; White RR; Rusconi CP; Sullenger BA; Church FC FEBS Lett; 2004 Jun; 568(1-3):10-4. PubMed ID: 15196911 [TBL] [Abstract][Full Text] [Related]
10. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098 [TBL] [Abstract][Full Text] [Related]
11. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II. Blinder MA; Tollefsen DM J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620 [TBL] [Abstract][Full Text] [Related]
13. Enhancement of heparin cofactor II anticoagulant activity. Bauman SJ; Church FC J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918 [TBL] [Abstract][Full Text] [Related]
14. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin. Holland CA; Henry AT; Whinna HC; Church FC FEBS Lett; 2000 Nov; 484(2):87-91. PubMed ID: 11068038 [TBL] [Abstract][Full Text] [Related]
15. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. Verhamme IM; Bock PE; Jackson CM J Biol Chem; 2004 Mar; 279(11):9785-95. PubMed ID: 14701814 [TBL] [Abstract][Full Text] [Related]
16. Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition. Ciaccia AV; Monroe DM; Church FC J Biol Chem; 1997 May; 272(22):14074-9. PubMed ID: 9162031 [TBL] [Abstract][Full Text] [Related]
17. Role of the proposed serpin-enzyme complex receptor recognition site in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes. Maekawa H; Tollefsen DM J Biol Chem; 1996 Aug; 271(31):18604-9. PubMed ID: 8702511 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease. Stone SR; Le Bonniec BF J Mol Biol; 1997 Jan; 265(3):344-62. PubMed ID: 9018048 [TBL] [Abstract][Full Text] [Related]
19. Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition. Roddick LA; Bhakta V; Sheffield WP BMC Biochem; 2013 Nov; 14():31. PubMed ID: 24215622 [TBL] [Abstract][Full Text] [Related]
20. Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex. Verhamme IM Anal Biochem; 2012 Feb; 421(2):489-98. PubMed ID: 22206940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]